The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•30 April 2026•

1 min read

Citi Raises AstraZeneca Earnings Forecast, Maintains Buy Rating After Q1 Beat

Key Facts

1Citi raised its 2026 core earnings per share forecast for AstraZeneca by 2% to $10.30.

2AstraZeneca's first-quarter results beat consensus by approximately 2% while full-year guidance remained unchanged.

Citi has increased its 2026 core earnings per share forecast for AstraZeneca by 2% to $10.30, while reiterating its 'buy' rating on the stock. This upward revision follows first-quarter financial results that beat consensus estimates by approximately 2%, even as full-year guidance remained unchanged. Analysts highlighted that the strong quarterly performance reinforces confidence in the company's long-term growth trajectory. Positive sentiment is also driven by anticipated drug pipeline catalysts, with significant clinical data readouts expected in the second half of the year. The move reflects a bullish outlook on the company's risk-reward profile within the global pharmaceutical sector. Investors are now monitoring AstraZeneca's ability to translate these forecasts into sustained market share growth.